Adherence Self-Efficacy Scale (ASES)

Abstract

The Adherence Self-Efficacy Scale (ASES) is a specialized psychometric instrument developed to quantify an individual’s confidence in their ability to adhere successfully to complex HIV treatment plans. These plans encompass a broad range of self-care behaviors beyond just taking antiretroviral (ART) medication regimens, including adherence to nutritional guidelines and exercise routines. The scale was initially designed for use within clinical trials focusing on behavioral interventions related to stress, coping, and treatment adherence.

Keywords

Adherence Self-Efficacy Scale, ASES, Self-efficacy, HIV, Antiretroviral Therapy, ART adherence, Behavioral intervention, Psychosocial measures, Treatment adherence.

Authors

Information regarding the original authors of the Adherence Self-Efficacy Scale (ASES) was not specified in the provided source content.

Purpose

The primary purpose of the ASES is to provide a reliable and valid measure of self-efficacy specific to adherence behaviors in individuals managing HIV. Given that adherence to treatment protocols is paramount for effective viral suppression and long-term health outcomes, quantifying confidence levels helps identify patients who may require targeted behavioral support.

The scale is designed to assess confidence across the spectrum of adherence behaviors required in an HIV treatment plan. This includes, but is not limited to, consistent administration of ART, maintaining prescribed nutritional intake, and engaging in recommended physical activity or exercise. The original instrument was developed specifically for research applications, particularly in clinical trials evaluating behavioral interventions.

Construct

The ASES measures the psychological construct of adherence self-efficacy, which is defined as an individual’s belief in their capacity to successfully execute the necessary actions to manage their medical condition. This construct is central to Self-efficacy Theory, positing that confidence is a critical determinant of behavioral initiation and perseverance, especially when facing obstacles or stress.

In the context of HIV, high adherence self-efficacy correlates strongly with better medication adherence and overall treatment integration, suggesting it acts as a protective psychological resource against challenges inherent in lifelong chronic disease management.

Validity

The concurrent validity of the ASES has been demonstrated through significant relationships observed between scale scores and several objective clinical and psychosocial outcomes. Specifically, validity analyses revealed correlations with key measures, including:

• ART Adherence: Strong predictive power regarding actual medication-taking behavior.
• Clinical Status: Relationships with biological markers indicative of effective HIV management.
• Psychosocial Measures: Links to other psychological variables relevant to stress, coping, and quality of life.
• Healthcare Utilization: Associations with patterns of engaging with healthcare services.

Reliability

The HIV-ASES demonstrates robust psychometric properties regarding its reliability. The scale exhibits excellent internal consistency, with reliability coefficients (ρs) consistently exceeding .90. This indicates a high degree of homogeneity among the scale items, suggesting they reliably measure the same underlying construct.

Furthermore, the scale exhibits strong temporal stability, or test-retest reliability. Reliability was confirmed over different intervals: strong reliability (rs > .70) was observed at the 3-month follow-up, and moderate, yet adequate, reliability (rs > .40) was maintained even at the extended 15-month follow-up period.

Factor Analysis

Factor analyses performed on the ASES items support a two-factor structure, which together account for 61% of the total variance observed in the scale items. These factors represent distinct facets of adherence self-efficacy:

• Adherence Integration: This factor, associated with a strong eigenvalue of 6.12, likely represents the confidence in incorporating treatment behaviors seamlessly into daily life routines.
• Adherence Perseverance: This factor, associated with an eigenvalue of 1.16, reflects confidence in maintaining adherence despite challenges, setbacks, or long-term fatigue inherent in chronic treatment.

Instrument

Test Type: Self-report scale; Psychometrics instrument

Format: Likert-type scale (Inferred, typical for self-efficacy measures)

Language Available: Not specified in the source content

Population Group: Individuals diagnosed with HIV

Age Group: Adults (Inferred from clinical trials context)

Population Details: Developed initially for use in behavioral intervention clinical trials addressing stress, coping, and treatment adherence among persons living with HIV.

Test Methodology: Quantitative assessment via questionnaire, typically administered in research or clinical settings to measure confidence levels regarding adherence behaviors.

Keywords

Psychometric scale, Internal consistency, Test-retest reliability, Concurrent validity, Adherence Integration, Adherence Perseverance.

Authors

Author ORCID Identifier: Unavailable

Affiliation Email addresses: Unavailable

Correspondence Address: Unavailable

Permissions & Fee and Test Year

Test Year: The original publication year was not specified in the source content.

Permissions and Fees: Information regarding necessary permissions for use or associated licensing fees is not available from the source material. Users should consult the primary publication source for distribution and usage rights.

The original PDF can be downloaded here: [Link to original PDF is not provided in the source content.]

Reference’s

Specific academic references detailing the development and validation of the Adherence Self-Efficacy Scale (ASES) were not provided in the source content.

Items of the Adherence Self-Efficacy Scale (ASES)

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.

The individual items comprising the Adherence Self-Efficacy Scale (ASES) were not included in the provided source content.